Amita Joshi

No ORCID on file · 2 papers in corpus
other 2022
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years
Human vaccines & immunotherapeutics ·doi:10.1080/21645515.2022.2078626

Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccin…

rct 2018
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America ·doi:10.1093/cid/cix797

BACKGROUND: The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical…